Tag Archive for: diabetes

ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics

Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize Manufacturing capacity more than triples, with initial capacity to support over 17,000 users Volume manufacturing drives gross margin expansion Utrecht, the Netherlands — May 28, 2026 ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, today announced that commercial‑scale production […]

Atrogi announces first subjects dosed in human trial for lead candidate ATR-258

First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight loss Study led by Associate Professor Morten Hostrup, a leading authority on β2-adrenergic receptor signaling in skeletal muscle at the University of Copenhagen, to evaluate muscle […]

Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium

Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) with associated macular edema Oral treatment was well tolerated, showed signs of clinical effect and retinal imaging data consistent with reductions in vascular leakage, one of the core […]

ViCentra Appoints Diabetes Commercialization Leader Reman McDonagh as Vice President, Global Marketing

Marketing executive brings 20+ years of global diabetes experience to support European scale-up and next-generation Kaleido launch readiness Utrecht, the Netherlands — January 29, 2026 ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, announced today that Reman McDonagh, PhD, has joined the Company as Vice President, Global Marketing. McDonagh’s appointment […]

ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access

Secures an additional $13 million, bringing the total to $98 million with new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, plus increased support from Innovation Industries Strengthens manufacturing scale-up and commercial operations in Germany, the Netherlands, and France, and advances U.S. market preparation Validates ViCentra’s strategy and team, […]

© Optimum Strategic Communications.